{"prompt": "['8.6', 'ASSESSMENTS FOR PREMATURE DISCONTINUATION FROM STUDY DOSING', '27', '8.7', 'PROCEDURES AND SPECIFICATIONS', '27', '8.7.1', 'Clinical Laboratory Analytes', '27', '8.7.2', 'Medical History', '28', '8.7.3', 'Quality of Life Surveys', '28', '8.7.4', 'Missed Visits', '28', '8.7.5', 'Mentorship', '28', '8.7.6', 'Location of Study Activities', '29', '9', 'ADVERSE EVENTS AND TOXICITY MANAGEMENT', '30', '9.1', 'DEFINITIONS OF ADVERSE Events, ADVERSE REACTIONS, AND SERIOUS ADVERSE Events', '30', '9.1.1', 'Adverse Events', '30', '9.1.2', 'Serious Adverse Events', '30', '9.1.3', 'Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or', 'Serious Adverse Events', '32', '9.2', 'ASSESSMENT OF ADVERSE Events AND SERIOUS ADVERSE Events', '32', '9.2.1', 'Assessment of Causality for Study Drugs and Procedures', '32', '9.2.2', 'Assessment of Severity', '32', '9.3', 'SPONSOR-INVESTIGATOR REQUIREMENTS AND INSTRUCTIONS FOR REPORTING ADVERSE Events AND SERIOUS', 'ADVERSE Events', '33', '9.4', 'CRI REPORTING REQUIREMENTS', '34', '9.5', 'CLINICAL LABORATORY ABNORMALITIES AND OTHER ABNORMAL ASSESSMENTS AS ADVERSE Events OR', 'SERIOUS ADVERSE Events', '34', '9.6', 'SUBJECT STOPPING RULES', '34', '9.7', 'SPECIAL SITUATIONS REPORTS', '35', '9.7.1', 'Definitions of Special Situations', '35', '9.8', 'REPORTING SPECIAL SITUATIONS', '35', '9.8.1', 'Instructions for Reporting Pregnancies', '35', '9.8.2', 'Reporting Other Special Situations', '36', '10', 'STATISTICAL CONSIDERATIONS', '37', '10.1', 'ANALYSIS OBJECTIVES AND ENDPOINTS', '37', '10.1.1', 'Analysis Objectives', '37', '10.1.2', 'Primary Endpoint', '37', '10.1.3', 'Secondary Enppoints', '37', '10.1.4', 'Safety Enppoints', '37', '10.1.5', 'Other Enppoints of Interest', '37', '10.2', 'ANALYSIS CONVENTIONS', '38', '10.2.1', 'Analysis Sets', '38', '10.3', 'DATA HANDLING CONVENTIONS', '38', '10.4', 'DEMOGRAPHIC DATA AND BASELINE CHARACTERISTICS', '38', '10.5', 'PRIMARY ANALYSIS', '38', '10.6', 'SECONDARY ANALYSIS', '38', '10.7', 'OTHER ANALYSES', '39', '11', 'SPONSOR-INVESTIGATOR RESPONSIBILITIES', '39', '11.1', 'Good CLINICAL PRACTICE', '39', '11.2', 'INSTITUTIONAL REVIEW BOARD (IRB)/INDEPENDENT ETHICS COMMITTEE (IEC) REVIEW AND APPROVAL', '39', '11.3', 'INFORMED CONSENT', '40', 'CRI 15-05 Protocol 13SEP2017', 'Page 3']['11.4 CONFIDENTIALITY', '40', '11.5', 'STUDY FILES AND RETENTION OF RECORDS', '40', '11.6', 'CASE REPORT FORMS', '41', '11.7', 'INVESTIGATIONAL MEDICINAL PRODUCT ACCOUNTABILITY AND RETURN', '41', '11.8', 'PROTOCOL COMPLIANCE', '42', '11.9', 'PROTOCOL MODIFICATIONS', '42', '11.10', 'STUDY MONITORING', '42', '11.11', 'STUDY AUDITING OR INSPECTIONS', '42', '11.12', 'STUDY DISCONTINUATION', '42', '11.13', 'FINANCE AND INSURANCE', '42', '11.14', 'STUDY REPORT AND PUBLICATIONS', '42', '12', 'REFERENCES', '44', '13', 'APPENDICES', '45', 'APPENDIX 1:', 'INVESTIGATOR SIGNATURE PAGE', '46', 'APPENDIX 2:', 'STUDY PROCEDURES TABLE', '47', 'APPENDIX 3:', \"QUESTIONNAIRE TO DETERMINE THE PARTICIPATING PSYCHIATRISTS' COMFORT WITH HCV\", 'MANAGEMENT 49', 'APPENDIX 4:', 'GSI GRADING SCALE FOR SEVERITY OF ADVERSE Events AND LABORATORY ABNORMALITIES', '50', 'APPENDIX 5:', 'PREGNANCY PRECAUTIONS, DEFINITION FOR FEMALE OF CHILDBEARING POTENTIAL, AND', 'CONTRACEPTIVE RECOMMENDATIONS', '73', 'APPENDIX 6:', 'HCV TREATMENT CURRICULUM', '75', 'CRI 15-05 Protocol 13SEP2017', 'Page 4']\n\n###\n\n", "completion": "END"}